CRISPR-Cas9 Multiplex Editing of the α-Amylase/Trypsin Inhibitor Genes to Reduce Allergen Proteins in Durum Wheat

被引:48
作者
Camerlengo, Francesco [1 ]
Frittelli, Arianna [1 ]
Sparks, Caroline [2 ]
Doherty, Angela [2 ]
Martignago, Damiano [2 ]
Larre, Colette [3 ]
Lupi, Roberta [3 ]
Sestili, Francesco [1 ]
Masci, Stefania [1 ]
机构
[1] Univ Tuscia, Dept Agr & Forestry Sci, Viterbo, Italy
[2] Rothamsted Res, Harpenden, Herts, England
[3] Impasse Therese Bertrand Fontaine, INRAE UR1268 BIA, Nantes, France
基金
英国生物技术与生命科学研究理事会;
关键词
CRISPR-Cas9; durum wheat; multiplex editing; tRNA processing system; ATI; GM-free; NCWS; wheat allergies; AMYLASE-TRYPSIN-INHIBITORS; INTESTINAL INFLAMMATION; SENSITIVITY; EXPRESSION; SUBUNITS; IDENTIFICATION; MUTAGENESIS; ACTIVATION; BIOLOGY; CDNA;
D O I
10.3389/fsufs.2020.00104
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Wheat and its derived foods are widespread, representing one of the main food sources globally. During the last decades, the incidence of disorders related to wheat has become a global issue for the human population, probably linked to the spread of wheat-derived foods. It has been ascertained that structural and metabolic proteins, like alpha-amylase/trypsin inhibitors (ATI), are involved in the onset of wheat allergies (bakers' asthma) and probably Non-Coeliac Wheat Sensitivity (NCWS). The ATI are a group of exogenous protease inhibitors, which are encoded by a multigene family dispersed over several chromosomes in durum and bread wheat. WTAI-CM3 and WTAI-CM16 subunits are considered among the main proteins involved in the onset of bakers' asthma and probably NCWS. A CRISPR-Cas9 multiplexing strategy was used to edit the ATI subunits WTAI-CM3 and WTAI-CM16 in the grain of the Italian durum wheat cultivar Svevo with the aim to produce wheat lines with reduced amount of potential allergens involved in adverse reactions. Using a marker gene-free approach, whereby plants are regenerated without selection agents, homozygous mutant plants without the presence of CRISPR vectors were obtained directly from T-0 generation. This study demonstrates the capability of CRISPR technology to knock out immunogenic proteins in a reduced time compared to conventional breeding programmes. The editing of the two target genes was confirmed either at molecular (sequencing and gene expression study) or biochemical (immunologic test) level. Noteworthy, as a pleiotropic effect, is the activation of the ATI0.28 pseudogene in the edited lines.
引用
收藏
页数:14
相关论文
共 35 条
  • [31] Multiplex CRISPR/Cas9 gene-editing platform in oil palm targeting mutations in EgFAD2 and EgPAT genes
    Bohari Bahariah
    Mat Yunus Abdul Masani
    Md Piji Mohd Al Akmarul Fizree
    Omar Abd Rasid
    Ghulam Kadir Ahmad Parveez
    Journal of Genetic Engineering and Biotechnology, 21
  • [32] Rational Improvement of Rice Yield and Cold Tolerance by Editing the Three Genes OsPIN5b, GS3, and OsMYB30 With the CRISPR-Cas9 System
    Zeng, Yafei
    Wen, Jianyu
    Zhao, Weibo
    Wang, Qiong
    Huang, Wenchao
    FRONTIERS IN PLANT SCIENCE, 2020, 10
  • [33] Down-Regulation of Rice Glutelin by CRISPR-Cas9 Gene Editing Decreases Carbohydrate Content and Grain Weight and Modulates Synthesis of Seed Storage Proteins during Seed Maturation
    Chandra, Deepanwita
    Cho, Kyoungwon
    Pham, Hue Anh
    Lee, Jong-Yeol
    Han, Oksoo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (23)
  • [34] Ethylene Response Factor (ERF) Family Proteins in Abiotic Stresses and CRISPR-Cas9 Genome Editing of ERFs for Multiple Abiotic Stress Tolerance in Crop Plants: A Review
    Debbarma, Johni
    Sarki, Yogita N.
    Saikia, Banashree
    Boruah, Hari Prasanna Deka
    Singha, Dhanawantari L.
    Chikkaputtaiah, Channakeshavaiah
    MOLECULAR BIOTECHNOLOGY, 2019, 61 (02) : 153 - 172
  • [35] Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System
    Hong, Cheol-Hwa
    Sohn, Hyun-Jung
    Lee, Hyun-Joo
    Cho, Hyun-Il
    Kim, Tai-Gyu
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (06) : 201 - 210